05.02.2013 • News

Recipharm Appoints Hans Lennernäs to Operating Board

Recipharm Pharmaceutical Development is pleased to announce the appointment of Dr Hans Lennernäs to the company's Board of Directors.

Dr. Hans Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery; controlling a budget of €24.5 million.

His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.

In addition to his academic achievements, Dr Lennernäs has built an entrepreneurial reputation by cofounding several companies including DuoCort Pharma, and Lidds, whilst investing in a number of patents.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.